journal article·2006-09-15

Optimization of a fibrin scaffold for sustained release of an adenoviral gene vector

Ailish Breen, Padraig Strappe, Anil Kumar, Timothy O'Brien, Abhay Pandit

Publisher page

Abstract

Abstract One of the major limitations of adenovirus as an efficient gene delivery vehicle is its transient nature of transgene expression. At present, no biodegradable release system exists that permits the sustained release of gene delivery. This study aimed to optimize a biodegradable fibrin scaffold for sustained adenoviral mediated gene delivery. Scaffold formulations were fabricated incorporating an adenoviral vector encoding β‐galactosidase, and each scaffold was incubated in elution fluid. The level of transfection of cells was measured to assess virus diffusion from each scaffold at different time periods. Results showed that viral particles were present in the elution fluid and had the ability to transfect cells at different time points. Depending on the scaffold formulation, variable rates of diffusion were seen. Analysis of scaffold microarchitecture using stereo pairs showed that variable pore depth is seen in different fibrin scaffold concentration, which may be a determining factor in the diffusion rate. It was concluded that sustained release of the adenovirus could be attained up to 192 h at the optimal concentration of 60 mg/mL fibrinogen and 4 IU thrombin. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res, 2006
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Viral Infectious Diseases and Gene Expression in Insects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (16)

Show source-provided references
1. Gene therapy for cutaneous wound repair
2. 10.1046/j.1524-475x.2000.00473.x10.1046/j.1524-475x.2000.00473.x ↗
3. 10.1016/j.ymthe.2004.02.01810.1016/j.ymthe.2004.02.018 ↗
4. 10.1016/S0039-6109(02)00194-910.1016/S0039-6109(02)00194-9 ↗
5. 10.1161/01.ATV.20.6.141410.1161/01.ATV.20.6.1414 ↗
6. 10.1016/j.ymthe.2003.10.00210.1016/j.ymthe.2003.10.002 ↗
7. 10.1016/S0002-9610(01)00771-110.1016/S0002-9610(01)00771-1 ↗
8. 10.1016/S0002-9610(01)00770-X10.1016/S0002-9610(01)00770-X ↗
9. 10.1089/107632704134839210.1089/1076327041348392 ↗
10. Angiogenesis for the treatment of vascular diseases
11. 10.1055/s-0037-161338910.1055/s-0037-1613389 ↗
12. 10.1177/08839115970120020210.1177/088391159701200202 ↗
13. 10.1016/0003-4975(94)91015-410.1016/0003-4975(94)91015-4 ↗
14. 10.1016/S0168-3659(00)00295-910.1016/S0168-3659(00)00295-9 ↗
15. 10.1089/10763270175333770810.1089/107632701753337708 ↗
16. 10.1007/s00240-003-0347-910.1007/s00240-003-0347-9 ↗